News & Announcements

May 2008:

Two Raleigh-based biotechnology companies, Arbovax, Inc., and Immunobiosciences, Inc., are teaming up to develop a safe and effective vaccine for dengue, a viral disease transmitted by mosquitoes. View the North Carolina Biotechnology Center announcement.

February 2008:

As part of ImmunoBiosciences' efforts to expand its research activities, IBI acquired through a lease, 4800 square feet of lab space in Raleigh, N.C. to be it's future research center. The research center is expected to be operational 2nd quarter of 2008.

February 2008:

Christopher S. Petty, PhD joined ImmunoBiosciences as Senior Research Scientist . Dr. Petty adds to the team over 7 years of experience in both human and animal viral immunology. Dr. Petty was most recently involved in investigating immune responses to respiratory viruses at the NIEHS in RTP, NC.

February 2008:

Kelly Cunningham has joined ImmunoBiosciences, Inc. with the position of Office Manager. She has a Bachelor's of Science Degree in Management from Baker University, Baldwin City, Kansas. Kelly brings 18 years of business experience from the manufacturing and the pharmaceutical industries to IBI and has a strong background in marketing and sales. She is a certified Team Facilititator as well as a certified ISO 9001 Internal Auditor.

January 2008:

Dr. Eid Haddad, previously Senior Scientist at ImmunoBiosciences , was promoted to V.P. of Research and Development.

December 2007:

ImmunoBiosciences successfully closed a secondary financing round and attracted a third investor, Riata Management, to the company. Riata Management joined Manti Resources and Winn Explorations as venture investors with representation on the Board.

December 2007:

ImmunoBiosciences signed a Sponsored Research Agreement with the University of Texas at Austin to conduct collaborative research with Dr. Maria Croyle, College of Pharmacy. The research will study the application of Immune Complex Vaccine technology to the efficacy of Adenovirus vectors for gene therapy.

November 2007 : North Carolina State University's Centennial Campus was named the Research Science Park of the Year in an award from the Association of University Research Parks. ImmunoBiosciences occupies offices in one of the new Venture buildings on the Centennial Campus which now houses more than 130 companies, government agencies, and NC State research units advancing technologies ranging from semiconductors to genomic tools. (See NCSU News)

November 2007:

ImmunoBiosciences signed a Sponsored Research Agreement with the Veterinary Laboratory Agencies (VLA), in Weybridge, U.K. The VLA is an Executive Agency of the Department for Environment, Food and Rural Affairs with a regional network of 16 labs in Scotland, Wales and the U.K. ImmunoBiosciences will conduct collaborative research with Dr. Martin Woodward on the application of AAC technology for development of a vaccine for a bacterial disease of pigs.

August 2007:

Dr. Eid Haddad presented a talk at the "Second Annual Targeted Immunotherapeutics and Vaccine Summit: Novel vaccines: Bridging Research, Development, and Production". The meeting was organized by Cambridge Health Institute (CHI) and held in Boston, MA from Aug 22-24. The title of his presentation was "antibodies in a complex (AAC); a Novel Approach in Vaccine Development".

June 2007:

ImmunoBiosciences, Inc. signed a Sponsored Research Agreement with the University of Texas Medical Branch, Galveston, Texas, to conduct collaborative research with Dr. Roberto Garofalo, Sealy and Smith Professor of Pediatrics, Department of Pediatrics. The research studies the application of the antibodies in a complex (AAC) for the development of a human respiratory virus vaccine.

June 2007:

ImmunoBiosciences, Inc. signed a Cooperative Research Agreement with North Carolina State University, Raleigh, North Carolina to conduct collaborative research with Dr. Barbara Sherry, Professor of Virology, College of Veterinary Medicine, Department of Molecular Biomedical Sciences. The research studies the application of the antibodies in a complex (AAC) for the development of a cattle respiratory virus vaccine and for a human respiratory virus vaccine.